



IC10 and PCT/PTO 28 JAN 2002

PATENT
0020-4848 P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: MORIKAWA et al. Conf.: 2810
Appl. No.: 09/806,568 Group: 1642
Filed: July 30, 2001 Examiner: UNASSIGNED
For: ENZYME PRODUCING PLASMA PROTEIN FRAGMENT
HAVING INHIBITORY ACTIVITY TO METASTASIS
AND GROWTH OF CANCER AND PLASMA PROTEIN
FRAGMENT PRODUCED BY FRAGMENTATION BY
SAID ENZYME TECHNICAL FIELD

RECEIVED
MAR 13 2002
TECH CENTER 1600/2900

REQUEST FOR A CORRECTED OFFICIAL FILING RECEIPT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Attached hereto is the Official Filing Receipt in connection
with the above-identified application.

THE FOLLOWING CORRECTION(S) IS/ARE RESPECTFULLY REQUESTED:

FOREIGN APPLICATIONS:

Please replace "JAPAN 10/296095 10/02/1998"

with --JAPAN 296095/1998 10/02/1998--

TITLE:

Please replace "Enzyme producing plasma protein
fragment having effect of inhibiting cancer metastasis and
plasma protein fragment fragmented by the enzyme"

with --Enzyme producing plasma protein fragment having
inhibitory activity to metastasis and growth of cancer and
plasma protein fragment produced by fragmentation by said
enzyme technical field--

8
160
320-02
1/28/02

It is respectfully requested that the U.S. Patent and Trademark Office forward/issue a new Filing Receipt with the correction(s) indicated above. Support for the correction(s) is readily apparent on the enclosed photocopy of the Declaration and Power of Attorney.

The correction(s) is/are due to error by the U.S. Patent and Trademark Office; therefore no fee is due.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Marc S. Weiner, #32,181

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

MSW/end

Attachment

(Rev. 03/19/01)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20530
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/806,568	07/30/2001	1642	1130	20-48414		15	1

CONFIRMATION NO. 2810

FILING RECEIPT



0C00000000863880

2292
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747



Date Mailed: 10/16/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Wataru Morikawa, Kumamoto-shi, JAPAN;
Kazuyoshi Kaminaka, Kumamoto, JAPAN;
Sumiyo Takemoto, Kumamoto-shi, JAPAN;
Hiroaki Maeda, Kumamoto-shi, JAPAN;
Chikateru Nozaki, Kumamoto-shi, JAPAN;
Seiji Miyamoto, Kumamoto, JAPAN;

RECEIVED
MAR 13 2002
TECH CENTER 1600/2300

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/05322 09/29/1999

Foreign Applications

JAPAN 10/296095 10/02/1998

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title



Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).